Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àΰ£ ´ëÀå¾Ï¿¡¼­ Bone Morphogenetic Protein 2 À¯ÀüÀÚÀÇ ÈÄÇâÀû º¯ÀÌ¿¡ °üÇÑ ¿¬±¸ A Study of Epigenetic Alteration of the Bone Morphogenetic Protein-2 Gene in Human Colorectal Cancer

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2010³â 26±Ç 1È£ p.53 ~ 61
Àå¿ë¼±, ÀåÁØÇõ, ±¸Áöȸ, ±è°æ·¡, ÃÖ¼±±Ù, ±è±¤, À±¹Î¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
Àå¿ë¼± ( Jang Yong-Sun ) 
ÀÎÇÏ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿Ü°úÇб³½Ç

ÀåÁØÇõ ( Jang Jun-Hyuk ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ »ýÈ­Çб³½Ç
±¸Áöȸ ( Koo Ji-Hoe ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è°æ·¡ ( Kim Kyung-Rae ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÃÖ¼±±Ù ( Choi Sun-Keun ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è±¤ ( Kim Kwang ) 
ÀÎÇÏ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿Ü°úÇб³½Ç
À±¹Î¿µ ( Yun Min-Young ) 
¹ÌÁî¸Þµðº´¿ø ¿Ü°ú

Abstract


Purpose: Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta family and play an important role in cellular growth. Recent reports suggest that exogenous bone morphogenetic protein-2 (BMP-2) acts as an antiproliferative agent in a variety of cell lines. We will study whether BMP-2 is altered in human colorectal cancer.

Methods: We analyzed 40 colorectal cancer cases and 6 colorectal cancer cell lines by using reverse transcription-polymerase chain reaction (RT-PCR) to determine the expression of BMP-2.

Results: Thirteen of 40 colorectal cancers (33%) and 3 of 6 colorectal cancer cell lines (50%) revealed decreased expression of BMP-2. The rates of decreased expression were 0% (0/7), 42.1% (8/19), 28.6% (2/7), 33.3% (2/6), and 100% (1/1) in stages I, II, III, and IV, respectively. Histologically, the rates were 33.3% (2/6), 32.2% (10/21), 50% (1/2), and 0% (0/1) in well-differentiated, moderately-differentiated, poorly-differentiated and mucinous cancers, respectively. As for location, the rates for colon and rectal cancers were 27.8% (5/18) and 36.4% (8/22), respectively. We identified methylation in the CpG island of the BMP-2 gene in 60% of colorectal cancer cells and in 50% of colorectal cancer cell lines. The 13 cases without BMP-2 gene expression showed no significant correlation with clinicopathological factors. Epigenetic silencing through DNA methylation is one of the key steps during carcinogenesis.

Conclusions: We found, through an analysis using the methylation-specific polymerase chain reaction technique, CpG island methylation of the BMP-2 promoter region in colorectal cancer. Thus, aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be related to colorectal carcinogenesis.

Å°¿öµå

´ëÀå¾Ï; BMP-2; ´ëÀå¾Ï Çü¼º
Colorectal cancer; BMP-2; Colorectal carcinogenesis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS